JP2023506642A5 - - Google Patents
Info
- Publication number
- JP2023506642A5 JP2023506642A5 JP2022537250A JP2022537250A JP2023506642A5 JP 2023506642 A5 JP2023506642 A5 JP 2023506642A5 JP 2022537250 A JP2022537250 A JP 2022537250A JP 2022537250 A JP2022537250 A JP 2022537250A JP 2023506642 A5 JP2023506642 A5 JP 2023506642A5
- Authority
- JP
- Japan
- Prior art keywords
- piperidine
- dione
- methoxy
- oxoisoindorin
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950048P | 2019-12-18 | 2019-12-18 | |
| US62/950,048 | 2019-12-18 | ||
| PCT/IB2020/062070 WO2021124172A1 (en) | 2019-12-18 | 2020-12-16 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506642A JP2023506642A (ja) | 2023-02-17 |
| JP2023506642A5 true JP2023506642A5 (https=) | 2024-01-30 |
| JP7682181B2 JP7682181B2 (ja) | 2025-05-23 |
Family
ID=73856242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537250A Active JP7682181B2 (ja) | 2019-12-18 | 2020-12-16 | ３－（５－メトキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11566022B2 (https=) |
| EP (1) | EP4076650B1 (https=) |
| JP (1) | JP7682181B2 (https=) |
| KR (1) | KR20220114065A (https=) |
| CN (1) | CN114828959B (https=) |
| AR (1) | AR120773A1 (https=) |
| AU (1) | AU2020410514A1 (https=) |
| BR (1) | BR112022011796A2 (https=) |
| CA (1) | CA3164832A1 (https=) |
| CO (1) | CO2022008243A2 (https=) |
| CR (1) | CR20220278A (https=) |
| DO (1) | DOP2022000121A (https=) |
| EC (1) | ECSP22055267A (https=) |
| ES (1) | ES2980575T3 (https=) |
| IL (1) | IL293530A (https=) |
| JO (1) | JOP20220152A1 (https=) |
| MX (1) | MX2022007351A (https=) |
| PE (1) | PE20230159A1 (https=) |
| PH (1) | PH12022551482A1 (https=) |
| PY (1) | PY2084899A (https=) |
| TW (1) | TW202130631A (https=) |
| UY (1) | UY38986A (https=) |
| WO (1) | WO2021124172A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023536657A (ja) * | 2020-08-07 | 2023-08-28 | コーネル ユニバーシティー | タンパク質をｅ３リガーゼの媒介によって分解するための、治療上有用なｃｕｒｅ－ｐｒｏ分子、ならびにその作製方法及び使用方法 |
| PY2217419A (es) | 2021-03-15 | 2022-09-27 | Novartis Ag | Derivados de pirazolopiridina y sus usos |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| KR20240053589A (ko) * | 2021-07-30 | 2024-04-24 | 하이노바 파마슈티컬스 인코포레이티드 | 이중 기능성 키메라 헤테로 고리 화합물 및 이의 안드로겐 수용체 분해제로서의 용도 |
| KR20240123836A (ko) * | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| EP4612128A4 (en) | 2022-11-04 | 2025-09-10 | Bristol Myers Squibb Co | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
| WO2024140638A1 (zh) * | 2022-12-27 | 2024-07-04 | 标新生物医药科技(上海)有限公司 | 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用 |
| CN115959976A (zh) * | 2022-12-30 | 2023-04-14 | 安徽诺全药业有限公司 | 一种甲氧基取代双环戊烷衍生物的制备方法 |
| WO2024255810A1 (en) * | 2023-06-15 | 2024-12-19 | Hangzhou Glubio Pharmaceutical Co., Ltd | Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof |
| WO2025076285A1 (en) * | 2023-10-06 | 2025-04-10 | Delphia Therapeutics, Inc. | Compounds, pharmaceutical compositions thereof, and methods of using the same |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2025137613A1 (en) * | 2023-12-22 | 2025-06-26 | Ganymede Oncology, Inc. | Cycloalkylene nrf2 protein degraders |
| US12565492B2 (en) | 2024-08-09 | 2026-03-03 | Triana Biomedicines, Inc. | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof |
| CN120717945A (zh) * | 2025-08-15 | 2025-09-30 | 泰迩生物医药泰州有限公司 | 一种(2r,4s)-n-boc-4-羟基哌啶-2-甲酸甲酯的合成方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| CA2433680A1 (en) | 2000-12-28 | 2002-08-01 | Gregory M Arndt | Double-stranded rna-mediated gene suppression |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| PL3202460T3 (pl) * | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| WO2012068512A1 (en) | 2010-11-18 | 2012-05-24 | Deuteria Pharmaceuticals Llc | 3-deutero-pomalidomide |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| US9133161B2 (en) | 2012-07-27 | 2015-09-15 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
| WO2017024019A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| EP3445765A4 (en) | 2016-04-22 | 2019-09-18 | Dana Farber Cancer Institute, Inc. | DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| BR112019015312A2 (pt) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| AU2018351050B2 (en) | 2017-10-18 | 2025-09-18 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2019079701A1 (en) | 2017-10-20 | 2019-04-25 | Dana-Farber Cancer Institute, Inc. | HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3765026A4 (en) | 2018-03-10 | 2021-12-22 | Yale University | BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| IL302595A (en) | 2018-04-13 | 2023-07-01 | Arvinas Operations Inc | Servalon ligands and bifunctional compounds containing them |
| AU2019294835B2 (en) | 2018-06-29 | 2025-04-17 | Dana-Farber Cancer Institute, Inc. | Ligands to cereblon (CRBN) |
| US12060366B2 (en) | 2018-06-29 | 2024-08-13 | Dana-Farber Cancer Institute, Inc. | Bispecific degraders |
| EP3814330A4 (en) | 2018-06-29 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
| US12030892B2 (en) | 2018-06-29 | 2024-07-09 | Dana-Farber Cancer Institute, Inc. | CRBN modulators |
| AU2019391016B2 (en) | 2018-12-03 | 2025-05-29 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of helios and methods of use |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
-
2020
- 2020-12-16 PH PH1/2022/551482A patent/PH12022551482A1/en unknown
- 2020-12-16 KR KR1020227024287A patent/KR20220114065A/ko not_active Withdrawn
- 2020-12-16 CR CR20220278A patent/CR20220278A/es unknown
- 2020-12-16 AR ARP200103501A patent/AR120773A1/es not_active Application Discontinuation
- 2020-12-16 PE PE2022001098A patent/PE20230159A1/es unknown
- 2020-12-16 IL IL293530A patent/IL293530A/en unknown
- 2020-12-16 TW TW109144481A patent/TW202130631A/zh unknown
- 2020-12-16 JP JP2022537250A patent/JP7682181B2/ja active Active
- 2020-12-16 AU AU2020410514A patent/AU2020410514A1/en not_active Abandoned
- 2020-12-16 MX MX2022007351A patent/MX2022007351A/es unknown
- 2020-12-16 PY PY202002084899A patent/PY2084899A/es unknown
- 2020-12-16 BR BR112022011796A patent/BR112022011796A2/pt not_active Application Discontinuation
- 2020-12-16 CA CA3164832A patent/CA3164832A1/en active Pending
- 2020-12-16 CN CN202080087049.9A patent/CN114828959B/zh active Active
- 2020-12-16 ES ES20828350T patent/ES2980575T3/es active Active
- 2020-12-16 WO PCT/IB2020/062070 patent/WO2021124172A1/en not_active Ceased
- 2020-12-16 EP EP20828350.7A patent/EP4076650B1/en active Active
- 2020-12-16 UY UY0001038986A patent/UY38986A/es not_active Application Discontinuation
- 2020-12-16 US US17/124,127 patent/US11566022B2/en active Active
-
2022
- 2022-06-13 CO CONC2022/0008243A patent/CO2022008243A2/es unknown
- 2022-06-14 DO DO2022000121A patent/DOP2022000121A/es unknown
- 2022-06-16 JO JOP/2022/0152A patent/JOP20220152A1/ar unknown
- 2022-07-14 EC ECSENADI202255267A patent/ECSP22055267A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023506642A5 (https=) | ||
| US20230346927A1 (en) | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | |
| US11844758B2 (en) | Therapeutically active compounds and their methods of use | |
| US11964953B2 (en) | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | |
| US11529356B2 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| JP6409081B2 (ja) | 治療活性化合物およびその使用方法 | |
| US11304946B2 (en) | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | |
| JP5687903B2 (ja) | キヌレニン産生抑制剤 | |
| JP2017500364A5 (https=) | ||
| JP2024521618A5 (https=) | ||
| JP2023525762A5 (https=) | ||
| TW201840549A (zh) | 2-雜芳基-3-氧代-2,3-二氫噠嗪-4-甲醯胺 | |
| TWI803600B (zh) | 新穎的三唑酮衍生物或其鹽及包含彼等之醫藥組合物 | |
| US11660301B2 (en) | Combination of ATR kinase inhibitors with PARP inhibitors | |
| JP2013523819A5 (https=) | ||
| US10894784B2 (en) | Heteroarylbenzimidazole compounds | |
| WO2018206547A1 (en) | Combination of bub1 and atr inhibitors | |
| US20240174683A1 (en) | Map4k1 inhibitors | |
| WO2018153971A1 (en) | Combination of atr kinase inhibitors | |
| US9695198B2 (en) | Factor IXa inhibitors | |
| US20240383875A1 (en) | Benzimidazole Pyridine Derivatives | |
| US20230405015A1 (en) | Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma | |
| RU2023130418A (ru) | Гетероциклические соединения | |
| EA048085B1 (ru) | Замещенные аминотиазолы в качестве ингибиторов dgkzeta для иммунной активации | |
| TW201726657A (zh) | 雜芳基苯并咪唑化合物 |